| Dr Katherine Marie Chastain, MD | |
|
2401 Gillham Rd, Kansas City, MO 64108-4619 | |
| (214) 234-3000 | |
| Not Available |
| Full Name | Dr Katherine Marie Chastain |
|---|---|
| Gender | Female |
| Speciality | Pediatrics - Pediatric Hematology-oncology |
| Location | 2401 Gillham Rd, Kansas City, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023281953 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 2013012603 (Missouri) | Secondary |
| 2080P0207X | Pediatrics - Pediatric Hematology-oncology | 2013016203 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Katherine Marie Chastain, MD 2401 Gillham Rd, Kansas City, MO 64108-4619 Ph: (816) 234-3000 | Dr Katherine Marie Chastain, MD 2401 Gillham Rd, Kansas City, MO 64108-4619 Ph: (214) 234-3000 |
News Archive
Unlike most home healthcare agencies, which have restricted the use of computer programs to such non-patient-care items as billing, the Visiting Nurse Service of New York has adopted advanced information technology in order to improve patient care. One of the results, documented in a new publication, is a significant 10% reduction in patient episodes ending in hospitalization, from 37% to 27% over the years 2001-2009.
Ambrx and Zhejiang Medicine Co. Ltd. today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx's most advanced internally developed site-specific antibody drug conjugate targeting Her2-positive breast cancer.
Inspire Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2010, reporting a net loss of $8.8 million or ($0.11) per share, an improvement from the second quarter of 2009 during which the Company incurred a net loss of $9.5 million or ($0.17) per share.
Vanda Pharmaceuticals Inc. announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda's anti-psychotic, in the U.S. and Canada. Fanapt(TM) was approved by the U.S. Food and Drug Administration on May 6, 2009 for the acute treatment of schizophrenia in adults.
› Verified 1 days ago
Ryan A Romans, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 Fax: 816-302-9939 | |
Amanda Finn, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 8781 N Platte Purchase Dr, Kansas City, MO 64155 Phone: 816-587-3200 Fax: 816-587-7644 | |
Samira Naime, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 Fax: 816-302-9939 | |
Dr. Tess Laurynn Schultz, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 Fax: 816-302-9939 | |
Delsie Asmarah Filardi, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-983-6763 Fax: 816-821-3081 | |
Gerald M Woods, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3265 | |
Dr. Gangaram Ganpatrao Akangire, M.D Pediatrics Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3593 |